NASDAQ:MEDP - Medpace Stock Price, News & Analysis

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace Holdings Inc (NASDAQ:MEDP) issued its earnings results on Monday, July, 29th. The company reported $0.81 EPS for the quarter, topping the consensus estimate of $0.63 by $0.18. The business earned $214.10 million during the quarter, compared to the consensus estimate of $200.99 million. Medpace had a return on equity of 17.65% and a net margin of 11.28%. The firm's revenue was up 25.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.61 EPS. View Medpace's Earnings History.

Medpace is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Medpace.

Medpace issued an update on its FY19 earnings guidance on Monday, July, 29th. The company provided EPS guidance of $2.83-2.93 for the period, compared to the Thomson Reuters consensus estimate of $2.65. The company issued revenue guidance of $840-860 million, compared to the consensus revenue estimate of $827.58 million.

4 Wall Street analysts have issued 12 month price targets for Medpace's shares. Their forecasts range from $62.00 to $85.00. On average, they expect Medpace's share price to reach $74.6667 in the next year. This suggests that the stock has a possible downside of 12.8%. View Analyst Price Targets for Medpace.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medpace.

Press coverage about MEDP stock has trended somewhat positive recently, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Medpace earned a daily sentiment score of 0.9 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Medpace.

Medpace saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 3,084,800 shares, an increase of 5.1% from the July 31st total of 2,936,000 shares. Based on an average daily trading volume, of 411,400 shares, the days-to-cover ratio is currently 7.5 days. Approximately 11.3% of the shares of the stock are short sold. View Medpace's Current Options Chain.

Some companies that are related to Medpace include Icon (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), National Research (NRC), Intrexon (XON), Sorrento Therapeutics (SRNE), STARPHARMA HOLD/S (SPHRY), Eloxx Pharmaceuticals (ELOX), Pieris Pharmaceuticals (PIRS), Luna Innovations (LUNA), Anavex Life Sciences (AVXL) and Bioanalytical Systems (BASI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include EXACT Sciences (EXAS), NVIDIA (NVDA), Alibaba Group (BABA), BioTelemetry (BEAT), Paycom Software (PAYC), Square (SQ), Paypal (PYPL), Coupa Software (COUP), Cisco Systems (CSCO) and ABIOMED (ABMD).

(MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.64%), BlackRock Inc. (12.64%), Vanguard Group Inc. (10.19%), Wasatch Advisors Inc. (5.59%), Pendal Group Ltd (4.29%) and Acadian Asset Management LLC (3.45%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership and Stephen P Ewald. View Institutional Ownership Trends for Medpace.

MEDP stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Bank of America Corp DE, Royal Bank of Canada, Acadian Asset Management LLC, D. E. Shaw & Co. Inc., ClariVest Asset Management LLC, Bernzott Capital Advisors and Chicago Equity Partners LLC. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc and Stephen P Ewald. View Insider Buying and Selling for Medpace.

MEDP stock was purchased by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., APG Asset Management N.V., BlackRock Inc., BlackRock Inc., Price T Rowe Associates Inc. MD, Invesco Ltd., Tributary Capital Management LLC and Marshall Wace LLP. View Insider Buying and Selling for Medpace.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MEDP stock can currently be purchased for approximately $85.65.

Medpace has a market capitalization of $3.07 billion and generates $704.59 million in revenue each year. The company earns $73.18 million in net income (profit) each year or $2.59 on an earnings per share basis. Medpace employs 2,900 workers across the globe.View Additional Information About Medpace.

The official website for Medpace is http://www.medpace.com/.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]